Mohammad Ali Mapar; Amir Hosein Roozbeh; Mohammad Bagher Mohammad Hasani
Volume 14, Issue 2 , 2011, , Pages 64-67
Abstract
Bachground: Erythroderma is a rare but serious skin disorder that may result from different causes. There are many publications on this subject, with a different incidence rate for each etiology. The aim of this study was to determine the frequency of erythroderma, and describe the incidence of each ...
Read More
Bachground: Erythroderma is a rare but serious skin disorder that may result from different causes. There are many publications on this subject, with a different incidence rate for each etiology. The aim of this study was to determine the frequency of erythroderma, and describe the incidence of each etiologic cause in patients indigenous to Khuzestan. Methods: In a retrospective study, we reviewed the files of patients diagnosed with erythroderma who were admitted to the dermatology ward of Sina Hospital, affiliated to Jondishapour Medical University of Ahvaz, southwest of Iran, in a period of 9 years from 1980 to 1989. We studied the clinical and pathology reports of patients and the final etiologic diagnosis. Results: Total admission was 6210 patients and the total number of erythrodermic patients was 85. The frequency of erythroderma in our dermatology department was 1.37%. The most common causes in order of frequency were eczema (32.94%), drug reaction (23.52%), psoriasis (21/18%), and malignancy (8.23%). Previous history of skin disease was found in 44 of 85 patients (51.76%) and 28 (32.9%) of them were suffering from eczema. The mean age of our patients was 49.11 years and the male-female ratio was 1.6:1. Conclusion: Erythroderma is a rare condition. The most common causes in our study were eczema and drug reactions; the high incidence of drug reactions in our patients compared to studies in other countries may be due to more administration of drugs in Iran, especially in Khuzestan.
Mohammad Ali Mapar; Sarah Hashemzade; Reza Yaghoobi
Volume 14, Issue 1 , 2011, , Pages 20-24
Abstract
Background: Topical corticosteroids and oral psoralen plus ultraviolet A radiation (PUVA therapy) are two common treatment methods for vitiligo. The aim of this study was to compare the efficacy, complications and patterns of repigmentation of these two methods. Methods: This prospective randomized clinical ...
Read More
Background: Topical corticosteroids and oral psoralen plus ultraviolet A radiation (PUVA therapy) are two common treatment methods for vitiligo. The aim of this study was to compare the efficacy, complications and patterns of repigmentation of these two methods. Methods: This prospective randomized clinical trial was conducted from July 2007 to October 2008. Patients with disseminated vitiligo were divided into two groups. PUVA therapy was administered in one group and topical clobetasol was used in the other group. Results were recorded in 4 categories and therapeutic findings and complications were compared after 24 weeks. Results: Among 37 participants in the PUVA therapy group, 18 (48.6%) patients achieved marked and 14 (37.8%) patients showed good repigmentation. Similarly, among 35 participants in the clobetasol group, 6 (17.1%) patients showed marked and 8 (22.8%) patients showed good repigmentation. treatment complications were observed in 16.2% of the participants in PUVA group and 28.6% of the participants in clobetasol group. The patterns of repigmentation were different in the two groups. Conclusion: PUVA showed better therapeutic effects, and did not cause significant complications. Therefore, it could be used as one of the first line medications in the treatment of vitiligo.